Chronic Lymphocytic Leukemia

>

Latest News

Venetoclax Monotherapy Shows Deep, Durable Responses in R/R CLL
Venetoclax Monotherapy Shows Deep, Durable Responses in R/R CLL

March 22nd 2024

Treatment with venetoclax appeared to improve responses in patients with relapsed or refractory chronic lymphocytic leukemia, according to findings from a phase 3b study.

Hoffmann Discusses Deciding Factors for Treating Patients With CLL
Hoffmann Discusses Deciding Factors for Treating Patients With CLL

March 19th 2024

Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL

March 15th 2024

FDA Approves Liso-Cel in Relapsed or Refractory CLL/SLL
FDA Approves Liso-Cel in Relapsed or Refractory CLL/SLL

March 15th 2024

Zanubrutinib Improves Survival, Response in Patients With CLL
Zanubrutinib Improves Survival, Response in Patients With CLL

March 7th 2024

More News